Skip to main content
PLOS One logoLink to PLOS One
. 2016 Mar 21;11(3):e0152341. doi: 10.1371/journal.pone.0152341

Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)

Keisuke Izumi, Yuko Kaneko, Misato Hashizume, Keiko Yoshimoto, Tsutomu Takeuchi
PMCID: PMC4801414  PMID: 26999019

The x-axis in Panel A within S5 Fig is labeled incorrectly. It should read: 10, 20, 30, 40. Please view the correct S5 Fig below.

Supporting Information

S5 Fig. Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX.

(TIF)

Reference

  • 1.Izumi K, Kaneko Y, Hashizume M, Yoshimoto K, Takeuchi T (2015) Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS ONE 10(12): e0145468 doi:10.1371/journal.pone.0145468 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S5 Fig. Predictive ability of OPN for CDAI remission in patients with RA who received TCZ with concomitant MTX.

(TIF)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES